Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Lead Pb 212-VMT01

Radiopharmaceutical · Kills target cells, directed at melanocortin-1 receptor (MC1R) (MC1R) · developed by Perspective Therapeutics

Phase 1/2 Most advanced trial

CATX Developer

1 Registered trials

What is Lead Pb 212-VMT01?

Lead Pb 212-VMT01 is a radioconjugate of the melanocyte-stimulating hormone receptor-targeting peptide VMT01 linked to the alpha-emitting radioisotope lead Pb 212. It binds MC1R, a G protein-coupled receptor upregulated on metastatic melanoma cells, delivering a cytotoxic dose of alpha radiation. It is studied in metastatic and recurrent melanoma.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: [212Pb]VMT01
Drug type: Radiopharmaceutical
Targets: melanocortin-1 receptor (MC1R) (MC1R)
Mechanism: Kills target cells, directed at melanocortin-1 receptor (MC1R) (MC1R)
Pathways: alpha radiation delivery to MC1R-expressing tumor cells
Therapy area: Oncology
Developer: Perspective Therapeutics (CATX)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT05655312	Phase 1/2	Recurrent Melanoma (Skin)	Recruiting	CATX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Melanoma Stage IIIMelanoma Stage IVMetastatic MelanomaRecurrent Melanoma (Skin)

Other drugs acting on MC1R

Gallium Ga 68-VMT02 Phase 1 Lead Pb 203-VMT01 Phase 1/2

More from Perspective Therapeutics

Gallium Ga 68-VMT02 Phase 1 Lead Pb 203-VMT01 Phase 1/2 Pb-PSV359 Phase 1/2 VMT-α-NET Phase 1/2

Sources

Updated Oct 11, 2026. Something wrong or missing? Report it on the CATX page.

Follow CATX, the company behind Lead Pb 212-VMT01

See CATX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CATX catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z